Check for updates

OPEN ACCESS

EDITED BY Kerstin Lenk, Graz University of Technology, Austria

REVIEWED BY Hubert Fiumelli, King Abdullah University of Science and Technology, Saudi Arabia Mani Ratnesh Singh Sandhu, Yale University, United States

*CORRESPONDENCE

Zoeb Jiwaji, i zoeb.jiwaji@ed.ac.uk Giles E. Hardingham, i giles.hardingham@ed.ac.uk

RECEIVED 03 May 2023 ACCEPTED 21 July 2023 PUBLISHED 21 August 2023

CITATION

Jiwaji Z, Márkus NM, McQueen J, Emelianova K, He X, Dando O, Chandran S and Hardingham GE (2023), General anesthesia alters CNS and astrocyte expression of activitydependent and activityindependent genes. *Front. Netw. Physiol.* 3:1216366. doi: 10.3389/fnetp.2023.1216366

COPYRIGHT

© 2023 Jiwaji, Márkus, McQueen, Emelianova, He, Dando, Chandran and Hardingham. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

General anesthesia alters CNS and astrocyte expression of activity-dependent and activity-independent genes

Zoeb Jiwaji^{1,2,3,4}*, Nóra M. Márkus^{1,2}, Jamie McQueen^{1,2}, Katie Emelianova^{1,2}, Xin He^{1,2}, Owen Dando^{1,2}, Siddharthan Chandran^{1,3} and Giles E. Hardingham^{1,2}*

¹UK Dementia Research Institute, Edinburgh Medical School, The University of Edinburgh, Edinburgh, United Kingdom, ²Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom, ³Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom, ⁴Department of Anaesthesia, Critical Care and Pain Medicine, Usher Institute, Edinburgh Royal Infirmary, Edinburgh, United Kingdom

General anesthesia represents a common clinical intervention and yet can result in long-term adverse CNS effects particularly in the elderly or dementia patients. Suppression of cortical activity is a key feature of the anesthetic-induced unconscious state, with activity being a well-described regulator of pathways important for brain health. However, the extent to which the effects of anesthesia go beyond simple suppression of neuronal activity is incompletely understood. We found that general anesthesia lowered cortical expression of genes induced by physiological activity in vivo, and recapitulated additional patterns of gene regulation induced by total blockade of firing activity in vitro, including repression of neuroprotective genes and induction of pro-apoptotic genes. However, the influence of anesthesia extended beyond that which could be accounted for by activity modulation, including the induction of non activityregulated genes associated with inflammation and cell death. We next focused on astrocytes, important integrators of both neuronal activity and inflammatory signaling. General anesthesia triggered gene expression changes consistent with astrocytes being in a low-activity environment, but additionally caused induction of a reactive profile, with transcriptional changes enriched in those triggered by stroke, neuroinflammation, and Aß/tau pathology. Thus, while the effects of general anesthesia on cortical gene expression are consistent with the strong repression of brain activity, further deleterious effects are apparent including a reactive astrocyte profile.

KEYWORDS

general anesthesia, transcriptional regulation, synaptic activity, astrocytes, neurodegenerating diseases

Introduction

General anesthesia (GA) is a common clinical intervention, with nearly 230 million surgical procedures taking place under GA across the world every year (Weiser et al., 2008). Exposure to anesthetic agents has been implicated in increasing neuronal apoptosis (Yon et al., 2005), worsening dementia neuropathology (Xie et al., 2008), increasing perioperative delirium (Robinson and Eiseman, 2008) and driving short and long-term memory impairment in humans and animals (Dutton et al., 2002; Culley et al., 2004; Pan et al., 2011; Bratzke et al., 2018). However, the molecular pathways by which anesthesia induces these deleterious effects is unclear.

Although the exact mechanisms by which GA agents work are yet to be fully elucidated, they are widely considered to suppress neuronal firing (Ries and Puil, 1993) via GABA receptor agonism or NMDA receptor antagonism (Chung et al., 2021). Anesthesia induces burst suppression on EEG (Lukatch et al., 2005), with both acute and long-lasting exposure to anesthesia being shown to dysregulate expression of selected activity-regulated immediate early genes (Upton et al., 2020). GA agents also have wider consequences on the CNS beyond those only through modulation of neuronal firing. They bind alternative non-GABA or non-NMDA receptors (Son, 2010); have global membrane effects via action on lipid-rafts (Pavel et al., 2020) and alter CNS blood flow (Slupe and Kirsch, 2018). Previous work by ourselves and others has established that neuronal activity is a key regulator of CNS transcription, driving cellular and circuitlevel changes necessary for memory and neuronal health (Bell and Hardingham, 2011; Deighton et al., 2014; Baxter et al., 2015; Hasel et al., 2017). However the extent to which anesthesia alters activity-regulated pathways important for brain health, as well as consequences on non-activity dependent pathways, was undetermined.

Beyond altering neuronal transcription, neuronal activity also has consequences on gene expression in nearby nonneuronal cells. Previously, we found that neuronal activity altered transcription in astrocytes (Hasel et al., 2017), the most common non-neuronal cell in the brain. These cells play important roles for CNS function including glutamate clearance (Anderson and Swanson, 2000), ionic regulation (Hertz and Chen, 2016), metabolic (Weber and Barros, 2015; Hasel et al., 2017) and antioxidant homeostasis (Jiwaji and Hardingham, 2022). We determined that neuronal activity upregulated astrocyte glycolytic gene expression, hence increasing the capacity of astrocytes to provide metabolic support to neurons (Hasel et al., 2017). However, the extent to which neuronal activity regulates astrocyte transcription in vivo, and whether anesthesia, by suppressing neuronal firing, altered previously identified astrocyte activity-dependent homeostatic pathways was unknown. Furthermore, astrocytes express GABA receptors (Chung et al., 2021) and anesthesia directly alters astrocyte calcium signaling (Thrane et al., 2012), lactate production (Hadjihambi et al., 2020), and gap junction formation (Liu et al., 2016). However, the extent to which anesthesia (via activity-dependent or activity-independent pathways) alters astrocyte transcriptional pathways was unknown.

In this study, we aimed to determine how anesthesia alters CNS and astrocyte transcriptional pathways. As anesthesia is associated with deleterious consequences, we aimed to identify consequences on CNS and astrocyte transcriptional pathways important for brain health. In addition, we aimed to identify the extent to which anesthesia-mediated gene expression changes overlapped with effects mediated through neuronal activity suppression vs. activity-independent effects in a whole brain situation.

Materials and methods

Animal husbandry

All procedures described were performed in compliance with the UK Animals (Scientific Procedures) Act 1986 and University of Edinburgh regulations, and carried out under project license numbers 70/9008 and P1351480E. Mice were group-housed in environmentally-enriched cages within humidity and temperature controlled rooms, with a 12-h light dark cycle (unless otherwise stated), with free access to food and water.

Transgenic mouse lines

The Aldh111-EGFP-Rp110a transgenic mouse line expressing an EGFP-tagged ribosomal protein 110a under the astrocyte-specific Aldh111 promoter was generated as previously described (Doyle et al., 2008) and re-derived on a C57B/6 background from frozen sperm imported from Jackson Laboratories (Mouse Strain Number—030248). Animals were utilised as heterozygotes in all experiments and mixed-sex unless otherwise stated.

Prolonged anesthesia

Six week old mice were induced in an anesthesia chamber with 4% isoflurane in oxygen, followed by maintenance anesthesia via facemask with 1.5% isoflurane. Mice were actively warmed to 36°C, and temperature, pulse, respiratory rate and oxygen saturations continuously monitored and maintained within normal physiological range using the Physiosuite monitoring system (Kent Scientific). 0.1 mL subcutaneous warmed sterile 0.9% saline solution was administered every 1–2 hrs to maintain hydration. Following anesthesia, mice were culled and whole neocortices rapidly dissected for RNAseq or TRAP analyses.

Visual deprivation and light stimulus

Four week old mice were transferred from standard lighting conditions to a temperature and ventilation controlled light-proof cabinet and housed in constant darkness for 6 days. All checks during this period were carried out in complete darkness using night-vision equipment. Mice were then exposed to a further 24 h of darkness or 24 h of continuous light, following which they were decapitated and visual cortices rapidly dissected.

Primary cortical neuronal culture

Primary cortical neurons were cultured from E17.5 CD1 mice embryos using a modified version of the protocol described by Bading and Greenberg, 1991. Cortices were dissected following decapitation in dissociation medium (DM) (mM: 81.8 Na2SO4, 30 K2SO4, 5.84 MgCL2, 0.252 CaCl2, 1 HEPES, 0.001% Phenol Red, 20 Glucose, 1 kyurenic acid, adjusted to pH 7.35 with NaOH). Tissue was enzymically digested by incubation with DM with 10 units/mL papain enzyme (Worthington Biochemicals) for 40 min with regular mixing, followed by two washes with DM and two washes with Neurobasal-A medium (Thermofisher) supplemented with 1% rat serum (Envigo), 1 x B-27 supplement (Thermofisher), 1 x Antimicrobial-Antifungal supplement (premixed penicillin, streptomycin and amphotericin B- Thermofisher) and 1 mM glutamine (Sigma). Following washing, cortices were mechanically dissociated with repeated mixing using a 5 mL serological pipette and the resulting cell-suspension diluted with Opti-MEM (Life Technologies) supplemented with glucose (20 mM) and Antimicrobial-Antifungal to achieve a final tissue concentration of 0.14 mouse cortical hemispheres.

0.5 mL of cell suspension was added to 24-well tissue-culture plates pre-coated with 0.5 mL of water with 0.5% laminin from mouse Engelbreth-Holm-Swarm sarcoma cells (Roche) and 1.33% poly-D-lysine (Sigma). Plates were incubated for 2.5 h at 37° C in a humidified 5% CO2 incubator. After this, plate medium was aspirated (along with dead or non-adherent cells) and replaced 1 mL Neurobasal-A medium supplemented with 1% rat serum, B-27, Antimicrobial-Antifungal and glutamine and 4.3 μ M of the antimitotic cytosine B-D-arabinofuranoside hydrochloride (AraC) to prevent glial growth. Cultures were subsequently fed at day *in vitro* (DIV) 4 with 1 mL of Neurobasal-A medium supplemented with 1% rat serum, B-27, Anti-Anti, glutamine and AraC.

Suppression of synaptic activity was achieved by changing cultured cells into serum-free base-medium (10% minimum essential media (MEM, Life Technologies) and 90% salt-glucose-glycine (SGG) containing in mM: 114 NaCl, NaHCO3, 5.292 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 1 Glycine, 30 Glucose, 0.5 sodium pyruvate, 0.1% Phenol Red) with 100 nM tetradotoxin (TTX, Tocris) on DIV9 for 24 h to inhibit neuronal action potential firing. Control conditions were placed into serum-free base-medium only.

RNA extraction

RNA extraction was carried out using the High Pure RNA Isolation Kit (Roche) as per manufacturer's instructions. Three wells of a 24 well cell-culture plate were lysed per sample and transferred into glass-fibre filter column assemblies. Following DNAse incubation for 15 min, the columns were washed, dried and RNA eluted in 30 μ L of elution buffer.

Low-yield RNA extraction (for example, following ribosomal pulldown) was carried out using the Absolutely RNA Nanoprep kit (Agilent) as per manufacturer's instructions. Samples were lysed in 100 μ L of lysis buffer with β -mercaptoethanol; mixed with equal volume of 80% sulfolane and added to silica-based fibre filter columns. DNAse treatment was carried out for 15 min; columns were washed and dried, and RNA eluted in 20 μ L of pre-warmed 60°C RNAse free water.

Translating ribosome affinity purification (TRAP)

Isolation of cell-type specific translating mRNA was carried out as previously described (Heiman et al., 2014). Briefly: tissue or cells were lysed in ice-cold lysis buffer (in mM: 20 HEPES, 10 MgCl₂, 150 KCl, 0.5 DTT) along with 100 µg/mL cyclohexamide (Sigma), cOmplete ULTRA protease inhibitors (Sigma) and RNAse inhibitors (Superasin-Life Technologies; RNAsin-Promega). Cell lysate was centrifuged to clear debris and solubilised with 1% NP40 and 30 mM 1,2-diheptanoyl-snglycero-3-phosphocholine (DHPC-Avanti Polar Lipids). Following further centrifugation, supernatants were added to pre-prepared anti-GFP (19C8 and 19F7 antibodies-Sloan Memorial Centre) coated magnetic beads Kettering (Dynabeads MyOne Streptavadin T1-Life Technologies). Following immunoprecipitation overnight at 4°C with continuous rotation, beads were washed four times. Cell-type specific mRNA, attached to immunoprecipitated GFP-tagged ribosomes, was isolated and purified using the Agilent Nanoprep kit described above. 50 µL of solubilised lysate ("input sample"-representing total RNA) was taken prior to immune-precipation and spun overnight at 4°C (same conditions as TRAP samples) before RNA-purification with TRAP samples.

Reverse-transcription PCR (rtPCR)

cDNA was generated using the Transcriptor First Strand cDNA Synthesis Kit (Roche). 7 μ L of RNA was added to the RT and buffer mixture prepared with random hexamers and oligoDT primers as per kit instructions, and rtPCR carried out with the following programme: 10 min at 25°C, 30 min at 55°C and 5 min at 85°C.

Quantitative PCR (qPCR)

qPCRs were performed on a Mx3000P QPCR machine (Agilent Technologies) using the FastStart Universal SYBR Green QPCR Master (Rox) (Roche) reagent. 6 ng of cDNA was used for each reaction and all qPCR results were carried out in duplicate or triplicate, along with no template controls and no RT controls where appropriate. The following cycling programme was used: 10 min at 95°C; 40 cycles of: 30 s at 95°C, 40 s at 60°C (with fluorescence detection), 1 min at 72°C; ending with dissociation curve: 1 min at 95°C and 30 s at 55°C with a ramp up to 30 s at 95°C with fluorescence detection. All data was normalised to house-keeping gene controls (*Rpl13a*). Table 1.

RNA-sequencing

Total RNA sequencing was performed by Edinburgh Genomics using Trueseq Stranded Total RNA V2 library preparation along with next-generation sequencing on the Illumina Novaseq 6000 platform. At-least 1 μ g RNA per sample was utilised, with RNA-integrity number (RIN) > 7. TRAP-sequencing (along with sequencing of matched inputs where appropriate) was performed by Cambridge Genomic Services, utilising the Clonetech - SMART-Seq v4 Ultra Low input RNA library preparation, along with sequencing on the Illumina Nextseq 500 platform. At least 1 ng RNA was used per sample with RIN > 7.

Gene	Forward (5'–3')	Reverse (5'–3')
Aif1	GCAATGATGAGGATCTGCC	CCACTGGACACCTCTCTAATTAATC
Aldh1l1	GTTGCTAGCCCAGAGCC	GGAACTTAAACACGGGCAC
Arc	AGTGGTGGGAGTTCAAGCAG	TCCTCAGCGTCCACATACAG
Bdnf	AAAGTCCCGGTATCCAAAGG	CTTATGAATCGCCAGCCAAT
Cx3cr1	CTGGTGGTCTTTGCCTTC	GCACTTCCTATACAGGTGTCC
Eno2	GCCATCTCCTGTAACTCTCC	ATTCTGTAAAGTTCCGAGCTTC
Gfap	GCAAAAGCACCAAAGAAGGGGA	ACATGGTTCAGTCCCTTAGAGG
Мbр	CCAGTCTAATAATGTCCATCGAC	CAGATTAACAAGATGCAGTATTGG
Mog	AAAGAATACCGACCAGAGAAATAC	CACATTGGTTCTCAGAGAAATAAG
Npy	AGACCTCTTAATGAAGGAAAGCAC	CAGGCAGACTGGTTTCAGG
Rpl13a	GATGAATACCAACCCCTCC	CGAACAACCTTGAGAGCAG

TABLE 1 Primer sequences.

Bioinformatics

RNA-seq reads were mapped using the STAR RNA-seq read aligner, version 2.5.3a, using default parameters. Tables of per-gene read counts were generated from the mapped read BAM files with featureCounts, version 1.5.2, using the -p parameter to specify fragments will be counted instead of reads in cases where the input data is paired-end, and the -s parameter set accordingly as the input data is unstranded or reversely-stranded. Gene annotations in GTF format were downloaded from Ensembl version 90. Differential gene expression analysis was performed in R using DESeq2, version 1.18.1, with betaPrior set to TRUE to perform fold change shrinkage, and the significance threshold calculated at a Benjamini-Hochberg adjusted p-value < 0.05, unless otherwise stated within the text. Gene ontology enrichment analysis was performed using the R package topGO, version 2.30.1, with the default "weight01" algorithm for dealing with the GO graph structure, and using Fisher's exact test statistic. Basic statistics about the RNA-sequencing data are provided in Supplementary Data S1.

Results

1. General anesthesia alters a large programme of cortical transcription and suppresses known activity-regulated immediate early genes.

We first set out to define how general anesthesia altered cortical transcription. Mice were exposed to 6 h isoflurane anesthesia, following which neocortices were dissected for RNA extraction and gene expression analysis using RNA-sequencing (RNAseq). Differential gene expression analysis revealed that anesthesia altered the expression of hundreds of CNS genes (Figure 1A; Supplementary Data S2-1). Ontology analysis of upregulated and downregulated genes (Figure 1B) highlighted anesthesia-associated upregulation of deleterious pathways including those for mitochondrial stress responses associated with apoptosis through

release of cytochrome C (*Hrk, Bid, Bbc3, Pmaip1, Plaur, Fas, Bmf*) and inflammation-induced responses including lipoxygenase synthesis (*Alox12b, Aloxe3, Alox8, Pla2g3*) and chemokine production (*Il4ra, Oas1c, Ticam1, Cyr61, Havcr2, Tlr7, Alox8, Trpv4*). Important pathways downregulated included those involved in the control of vasculature (*Apln, Arhgap42, Cx3cl1, Ahr, Dock5, Dusp5*) and neural maturation (*Bcl2, Dleu2, Lrrk2, Mir212, Mir132, Ngf*) and differentiation (*Bdnf, Notch1, Hdac5, Tmem119*).

The mechanism of action for most anesthesia agents is considered to be via inhibition of neuronal firing by GABA activation and NMDA receptor inhibition. We therefore investigated the consequences of anesthesia on immediate early genes previously described to be upregulated by neuronal firing (Lin et al., 2008; Lacar et al., 2016). We found that anesthesia is a potent suppressor of immediate early genes including downregulating activity-regulated genes that have previously been described to have neuroprotective or pro-synaptogenesis properties (*Bdnf, Arc, Npas4, Homer*) (Lin et al., 2008; Kim et al., 2018; Pollina et al., 2023) (Figure 1C, qPCR validation of selected IEGs in Supplementary Figure S11).

2. Visual sensory-deprivation and light re-exposure stimulation to determine CNS activity-regulated genes.

Neuronal firing is a key regulator of CNS transcription (Papadia et al., 2008; Léveillé et al., 2010; Bell and Hardingham, 2011; Baxter et al., 2015; Qiu et al., 2020). Having identified that anesthesia suppresses a limited set of markers previously described to be associated with neuronal firing, we next set out to determine more completely the extent to which anesthesia alters the expression of genes that are controlled by neuronal activity.

To better define CNS genes regulated *in vivo* by neuronal activity, we used a visual sensory deprivation and light-exposure paradigm. This allowed us to create conditions of altered neuronal activity in the visual cortex (Figure 2A). Mice were kept in complete darkness for 7 days to suppress visual cortex neuronal activity, and gene expression changes were compared to mice kept in normal light

0.00116 12.9

0.00136

0.00419 7.9 5.3

0.00126 5.1

0.0194 4.5 4.2

0.05570

0.01214 4.2

0.04658 3.7 3.4

0.00672

0.02080 3.1

0.00339 8.7

0.01044 8.7

0.00113 8.5

6 0.00038 8.3

3.0

18.3 0.00143 12.2

9.1

8.4

8.3 0.00159 6

10.8 9.2

> 7.2 6.3

> 5.4

4.3

4.3

4 0



GO:0033612	receptor serine/threonine kinase binding	19	7	0.04801	8.9
GO:0061578	Lys63-specific deubiquitinase activity	11	4	0.00337	8.7
GO:0042923	neuropeptide binding	16	5	0.0022	6.9
GO:0071837	HMG box domain binding	13	4	0.00662	6.8
GO:0004879	nuclear receptor activity	37	11	0.000009*	6.5
GO:0004993	G protein-coupled serotonin receptor activity	16	4	0.01452	5.1
GO:0035035	histone acetyltransferase binding	25	6	0.00352	4.8
GO:0045499	chemorepellent activity	28	6	0.00639	4.2
GO:0008083	growth factor activity	73	15	0.000032	4.0
GO:0005125	cytokine activity	69	14	0.000041	3.9

FIGURE 1

Consequences of anesthesia on cortical transcription. (A) RNAseq used to determine cortical gene expression changes in mice exposed to 6 h isoflurane anesthesia. Genes significantly induced (red) and repressed (blue) are highlighted (expression cut-off > 1 FPKM, > 1.3 FC up or down, p values adjusted for multiple testing by the Benjamini–Hochberg procedure to give a false discovery rate of 5% (p_adj < 0.05) here and in all RNA-seg analyses; n = 5 animals per condition). (B) Ontological analysis of genes induced and repressed by anesthesia. Top ten most significantly enriched pathways are shown, with pathways with less than four significant genes or not relevant to tissue type omitted. (C) Fold change expression of immediate early and activity-regulated neuroprotective genes in mice undergoing 6 h isoflurane anesthesia v controls (Mean ± SEM fold change anesthesia v control, N = 5 animals per condition, *p_adj < 0.05, overall p-value < 0.001, 1-way ANOVA, all gene expression data shown here and elsewhere, unless otherwise stated, determined using RNA-sequencing).

conditions (standard 12:12 light: dark cycle), as well as those exposed to complete darkness for 6 days and then re-exposed to light for 24 h (light re-exposure) (Figure 2B).

We confirmed that the expression of known immediate-early genes is reduced in animals kept in darkness for 7 days and elevated in animals kept in darkness and then re-exposed to light for 24 h (Figure 2C, qtPCR validation of selected IEGs in Supplementary Figure S11). Using RNAseq followed by differential gene expressionanalysis, we identified visual cortex genes up and downregulated by normal light v darkness (Figure 2D; Supplementary Data S2-2). Light re-exposure following darkness significantly altered a smaller number of genes as compared to mice always kept in normal light conditions (Figure 2E; Supplementary Data S2-3). However, there was a strong correlation in the directionality and magnitude of change between those genes significantly changed in the context of normal light-conditions v darkness with those changed by light reexposure (Figure 2F).

3. Anesthesia suppresses visual stimulation-mediated gene expression.

Given that anesthesia is proposed to act as an inhibitor of neuronal firing, we next determined the extent to which genes altered by visual sensory experience were also regulated by anesthesia. We found, as predicted, that anesthesia overall significantly suppressed genes upregulated by visual sensory



FIGURE 2

Visual sensory deprivation and light-re-exposure determines activity-mediated CNS gene expression. (A) Visual cortex innervation from the retina allows manipulation of neuronal activity by exposure to conditions of light v darkness. (B) Schematic of experimental protocol. Mice were kept in normal light conditions, total darkness for 7 days, or total darkness for 6 days followed by 24 h of light-re-exposure. (C) Fold change immediate early gene expression in mice exposed to normal light conditions, 7 days of darkness or 6 days of darkness followed by 24 h light re-exposure v mean expression in mice kept in darkness (mean \pm SEM, ****p*-value < 0.001, 1-way ANOVA, N = 4 mice per condition here and in all experiments involving visual sensory deprivation and light-stimulation). (D) RNAseq analysis reveals the consequences of visual sensory deprivation on visual cortex gene expression. Genes significantly induced by normal light conditions v darkness (red) and repressed (blue) are highlighted (expression cut-off > 1 FPKM, FC up or down > 1.3, p_adj < 0.05). (E) 24 h light re-exposure v darkness (red) and repressed (blue) are highlighted (expression. Genes significantly induced or repressed by 24 h light re-exposure v darkness (red) and repressed (blue) are highlighted (expression cut-off > 1 FPKM, FC up or down > 1.3, p_adj < 0.05). (F) Gene expression changes after 24 h light re-exposure v darkness in mice correlated with changes identified in mice kept in normal light conditions v darkness. Significantly altered genes in either paradigm are plotted to show log2 fold change expression in normal light v darkness and 24 h light-exposure v darkness (R2 and *p*-value from Pearson correlation).

experience. This was observed both in conditions of normal light v darkness and light re-exposure v darkness (Figure 3A), with light-stimulated gene-sets being significantly enriched for genes found to

be suppressed by anesthesia (Figure 3B). However, those genes suppressed by light-stimulation were not overall upregulated by anesthesia as predicted (Supplementary Figure S3).



regulated genes are significantly enriched for genes suppressed by anesthesia. Genes induced > 2 fold by normal light conditions or > 1.5 fold in light re-exposure (expression cut-off > 1 FPKM, $p_adj < 0.05$) taken and enrichment analysis performed using genes found to be downregulated (expression cut-off > 1 FPKM, $p_adj < 0.05$, > 2 FC) by anesthesia. Fold enrichment is shown, and 95% confidence interval (CI) of the fold enrichment depicted by the error bar. (*p < 0.05 two-sided Fisher's exact test).

4. Total neuronal activity blockade *in vitro* reveals an extended set of activity-regulated genes altered by anesthesia beyond those demonstrated by visual-sensory deprivation.

We next set out to better understand the identified discordance between how anesthesia altered those genes enhanced or suppressed by visual sensory stimulation. One possible reason was that the level of activity suppression achievable in the visual cortex by darkness was limited. Indeed, the mouse visual cortex receives innervation from other cortical areas, and therefore even in darkness there exists an element of background neuronal firing (Keller et al., 2012).

Therefore, we asked to what extent anesthesia altered CNS geneexpression by suppressing neuronal activity to a level beyond that possible by visual sensory deprivation alone. To determine genes altered by complete neuronal blockade, we used an *in vitro* primary mouse cortical neuronal culture system as previously described (Baxter et al., 2021). Primary mouse cortical neurons were cultured until day *in vitro* (DIV) 10 (by which time they have developed mature synapses with robust synaptic activity (Hasel et al., 2017)), and then placed into fresh medium containing 100 nM tetrodotoxin (TTX)—a voltage-gated sodium channel blocker that completely stops neuronal firing. Following neuronal activity blockade for 24 h, cells were lysed and RNA extracted for gene expression analysis via RNAseq, and compared to control neurons kept in TTX free medium.

Using differential gene expression, we identified genes altered by complete neuronal activity blockade (Supplementary Data S2-4) and determined that overall anesthesia strongly upregulated genes enhanced by complete neuronal activity blockade (Figure 4A), and strongly downregulated genes suppressed by neuronal activity blockade (Figure 4B), finding that genes increased or decreased *in vitro* by neuronal activity blockade were significantly enriched for genes upregulated or downregulated respectively by anesthesia (Figure 4C). Genes upregulated by TTX blockade included previously identified activity-suppressed pro-death genes (Léveillé et al., 2010). These genes were also significantly upregulated by anesthesia (Figure 4D), but not in the context of visual sensory deprivation (data not shown).

Overall, these data suggest that anesthesia drives suppression of neuronal firing beyond that achieved by visual sensory deprivation, leading to upregulation of detrimental genes normally suppressed by neuronal activity.



FIGURE 4

Consequences of anesthesia on genes altered by neuronal-activity blockade *in vitro*. (A) Anesthesia overall upregulates genes enhanced by neuronal activity blockade (genes upregulated following 24 h 100 nM TTX in neuronal culture, expression cut-off > 1 FPKM, FC > 2, p_adj < 0.05). Fold change anesthesia v control shown (expression cut-off > 1 FPKM, ratio paired 2-tailed *t*-test). (B) Anesthesia overall downregulates genes enhanced by neuronal activity blockade. Fold change anesthesia v control shown (expression cut-off > 1 FPKM, ratio paired 2-tailed *t*-test). (C) Genes altered up or down by neuronal activity blockade *in vitro* are significantly enriched for genes respectively enhanced or suppressed by anesthesia. Enrichment analysis performed on genes induced or suppressed by TTX using genes found to be upregulated and downregulated (expression cut-off > 1 FPKM, p_adj < 0.05, > 1.5 FC) by anesthesia. Fold enrichment is shown, and 95% confidence interval (CI) of the fold enrichment depicted by the error bar. (**p*-value < 0.05 two-sided Fisher's exact test). (D) Activity-regulated pro-death genes found to be upregulated by neuronal activity blockade *in vitro*, are also upregulated by *in vitro* neuronal activity blockade using TTX (expression of pro-death genes upregulated by *in vitro* neuronal activity blockade using TTX (expression cut-off 1 FPKM, p_adj < 0.05) following 6 h isoflurane anesthesia (Mean <u>±</u> SEM fold change expression anesthesia v control, N = 5 animals per condition, *p_adj < 0.05, overall *p*-value < 0.001, 1-way ANOVA).

5. Anesthesia alters the expression of genes not regulated by neuronal activity.

We next set out to identify genes altered by anesthesia that are not regulated by neuronal firing. We created a combined list of genes altered by visual sensory experience (changed normal light v dark, or light re-exposure v dark) or changed *in vitro* by blockade of neuronal activity using TTX (expression cut-off > 1 FPKM, unadjusted *p*-value < 0.1). By using a higher unadjusted *p*-value, we ensured a higher threshold to capture all genes that were possibly activitydependent in any of the stimulation paradigms. We determined genes regulated up or down by anesthesia that were not within this possible activity-dependent set (Figure 5A; Supplementary Data S2-5) and confirmed that anesthesia-regulated activity-independent genes were not altered by light-stimulus or TTX blockade (Figure 5B). Ontological analyses of activity-independent genes upregulated by anesthesia found enrichment for inflammationassociated pathways including chemokine production (*Il4ra*, *Oas1c*, *Ticam1*, *Havcr2*, *Tlr7*, *Alox8*, *Trpv4*), arachidonic acid synthesis (*Aloxe3*, *Cyp1b1*, *Alox8*, *Cyp2s1*, *Dagla*) and apotosis/ necroptosis pathways (*Pmaip1*, *Plaur*, *Fas*, *Bmf*, *Itpk1*, *Birc3*, *Fas*, *Pygl*) (Figure 5C).



С	UP Anesth	esia and N	ot Regulat	ed by No	euron	al Acti	vity

00.10	do territs - biological Processes	Annotated	Significant	rauj	Ratio
GO:0019369	arachidonic acid metabolic process	24	5	0.00196	9.3
GO:0032722	positive regulation of chemokine production	38	7	0.00107	8.1
GO:0043537	negative regulation of blood vessel endothelial ce Il migration	28	5	0.00081	7.7
GO:0090200	positive regulation of release of cytochrome c fro m mitochondria	25	4	0.00463	6.7
GO:0070266	necroptotic process	26	4	0.01905	6.4
GO:0001569	branching involved in blood vessel morphogenesi s	33	5	0.0079	6.3
GO:0034142	toll-like receptor 4 signaling pathway	27	4	0.00384	6.2
GO:0045429	positive regulation of nitric oxide biosynthetic pro cess	29	4	0.00797	5.7
GO:0007095	mitotic G2 DNA damage checkpoint signaling	30	4	0.009	5.4
GO:0032728	positive regulation of interferon-beta production	31	4	0.01011	5.2

GO.ID	GO Terms - Molecular Functions	Annotated	Significant	Padj	Odds Ratio
GO:0050431	transforming growth factor beta binding	18	4	0.00144	9.9
GO:0005125	cytokine activity	69	8	0.00578	4.6
GO:0030170	pyridoxal phosphate binding	38	4	0.0222	4.1
GO:0005506	iron ion binding	85	8	0.00803	3.6
GO:0020037	heme binding	65	5	0.03727	2.9
GO:0030414	peptidase inhibitor activity	73	4	0.08271	2.0
GO:0016798	hydrolase activity, acting on glycosyl bonds	87	4	0.08281	1.7
GO:0008289	lipid binding	549	19	0.08417	1.2
GO:0003824	catalytic activity	4009	98	0.03565	0.8

DOWN Anesthesia and Not Regulated by Neuronal Activity

GO.ID	GO Terms - Biological Processes	Annotated	Significant	Padj	Odds Ratio
GO:2000352	negative regulation of endothelial cell apoptotic p rocess	21	4	0.00168	9.2
GO:0048663	neuron fate commitment	45	8	0.00069	8.6
GO:0034391	regulation of smooth muscle cell apoptotic proce ss	23	4	0.02496	8.2
GO:2000737	negative regulation of stern cell differentiation	24	4	0.01691	7.8
GO:0002052	positive regulation of neuroblast proliferation	26	4	0.00379	7.1
GO:0001755	neural crest cell migration	50	7	0.00419	6.4
GO:1902895	positive regulation of miRNA transcription	38	5	0.00248	5.9
GO:0032728	positive regulation of interferon-beta production	31	4	0.00724	5.8
GO:0032720	negative regulation of tumor necrosis factor prod uction	34	4	0.01006	5.2
GO:0045665	negative regulation of neuron differentiation	70	8	0.01457	5.1
0.0.10			01	D-4	0.11
GOID	GO Terms - Molecular Functions	Annotated	Significant		
				Pauj	Ratio
GO:0005112	Notch binding	22	4	0.002	Ratio
GO:0005112 GO:0061578	Notch binding Lys63-specific deubiquitinase activity	22	4	0.002	Batio 8.8
GO:0005112 GO:0061578 GO:0045499	Notch binding Lys63-specific deubiquitinase activity chemorepellent activity	22 11 28	4 3 4	0.002 0.0022 0.0049	8.8 8.8 14.8 6.6
GO:0005112 GO:0061578 GO:0045499 GO:0001228	Notch binding Lys83-specific deubiquitinase activity chemorepatient activity DNA- binding transcription activator activity, RNA poly merase II-specific	22 11 28 297	4 3 4 15	0.002 0.0022 0.0049 0.0077	8.8 14.8 6.6 2.1
GO:0005112 GO:0061578 GO:0045499 GO:0001228 GO:0008083	Notch binding UydS-specific deublquitnase activity chemorepallent activity DNA- binding transcription activitor activity, RNA poly merase ii-specific growth factor activity	22 11 28 297 73	4 3 4 15 6	0.002 0.0022 0.0049 0.0077 0.0097	8.8 14.8 6.6 2.1
GO:0005112 GO:0061578 GO:0045499 GO:0001228 GO:0008083 GO:0001227	Notch binding Lys83-specific doublequitinase activity chemospellent activity ONA- binding transcription activator activity, RNA poly merase il-specific activity growth factor activity ONA- binding transcription repressor activity, RNA poly merase il-specificon repressor activity, RNA poly	22 11 28 297 73 223	4 3 4 15 6 12	0.002 0.0022 0.0049 0.0077 0.0097 0.0103	0003 Ratio 8.8 14.8 6.6 2.1 3.5 2.3
GO:0005112 GO:0061578 GO:0045499 GO:0001228 GO:0008083 GO:0001227 GO:0008201	Notch binding Lyst5-specific deubiquitinase activity chemorepailent activity DNA- binding transcription activator activity, RNA poly merase il-specific provih factor activity DNA- binding transcription repressor activity, RNA poly merase il-specific hegerin binding	22 11 28 297 73 223 97	4 3 4 15 6 12 7	0.002 0.0022 0.0049 0.0077 0.0097 0.0103	Odds Ratio 8.8 14.8 6.6 2.1 3.5 2.3 3.1 3.1
GO:0005112 GO:0061578 GO:0045499 GO:0001228 GO:0008083 GO:0001227 GO:0008201 GO:0008201	Notch binding Lys83-specific deubiquitinase activity chemorepatient activity DNA- binding transcription activitor activity, RNA poly merase il-specific growth factor activity DNA- binding transcription repressor activity, RNA poly merase il-specific merases il-specific heppint binding phosphaticity/insolid-4-phosphate binding	22 11 28 297 73 223 97 25	4 3 4 15 6 12 7 7 3	0.002 0.0022 0.0049 0.0077 0.0097 0.0103 0.0107 0.0236	Odds Ratio 8.8 14.8 14.8 6.6 2.1 3.5 3.5 2.3 3.1 5.4
GC:0005112 GC:0061578 GC:0045499 GC:0001228 GC:0008083 GC:0001227 GC:0008201 GC:0008201 GC:0070273 GC:0035035	Notch binding Lys83-specific doubleputinase activity chemorepatient activity ONA- binding transcription activator activity, RNA poly menses II-specific activity ONA- binding transcription repressor activity, RNA poly menses II-specificor repressor activity, RNA poly menses II-specific activity ONA- hepain binding phosphatality/imositol-4-phosphate binding	22 11 28 297 73 223 97 25 25	4 3 4 15 6 6 12 7 7 3 3 3 3	0.002 0.0022 0.0049 0.0077 0.0097 0.0103 0.0107 0.0236	Odds Ratio 8.8 14.8 14.8 6.6 2.1 3.5 3.5 2.3 3.1 5.4 5.4 5.4

FIGURE 5

Anesthesia alters genes not regulated by neuronal activity. (A) Anesthesia-regulated genes (FPKM cut-off > 1, $p_adj < 0.05$, FC > 1.3) not regulated by neuronal activity identified by removing possible activity-regulated genes. These are genes found to be changed in normal light v dark conditions, 24 h light-re-exposure or with neuronal-activity blockade *in vitro* (expression cut-off > 1 FPKM, unadjusted *p*-value < 0.1). (B) Confirmation that identified non-activity-mediated anesthesia-regulated genes are not altered *in vivo* by visual sensory stimulation or *in vitro* by neuronal-activity blockade. Log2 fold change expression in normal light conditions v darkness (top) or in TTX v control (bottom) shown for activity-independent genes identified as shown in (A). (C) Ontological analysis of non-activity-regulated genes induced or repressed by anesthesia. Top ten most significantly enriched pathways are shown, with pathways with less than 4 significant genes or not relevant to tissue type omitted.

6. TRAPseq allows identification of astrocyte-specific geneexpression changes

Neuronal activity, besides influencing transcription in neurons, also alters transcription in nearby non-neuronal cells (Saab et al., 2016; Hasel et al., 2017; Ioannou et al., 2019). In our previous work, we described how neuronal activity alters transcription in astrocytes to regulate genes involved in astrocyte glycolysis and the astrocyte-neuron lactate shuttle (Hasel et al., 2017), a pathway important for CNS energy provision (Bélanger et al., 2011). We therefore wanted to understand the extent to which anesthesia influenced activityregulated transcriptional pathways in astrocytes. Given that anesthesia has also been found to influence astrocyte signalling and functions, including altering calcium activity and lactate production, we hypothesised that anesthesia would have both activity-dependent and activity-independent effects.

We separated astrocyte-specific gene expression changes from those in other CNS cell-types using translating ribosome affinity purification (TRAP) (Heiman et al., 2014). This uses the transgenic



marker (Iba1); scale bar 50 u/M. (B) Schematic of TRAP protocol, allowing isolation of astrocyte-specific marker (ivenocriforing and microgular specific astrocyte-specific mRNA via immunoprecipitation of EGFP-tagged astrocyte ribosomes. (C) TRAPseq successfully enriches for astrocyte-specific markers and depletes for marker for other CNS cell-types. Mean fold change enrichment or depletion of cell-type specific gene markers following TRAP v pre-TRAP (input) sample (Mean \pm SEM fold change TRAP v input, ***p < 0.001, 1 way ANOVA).

Aldh111-EGFP-Rp113a TRAP transgenic mouse line, where eGFPtagged ribosomes are expressed specifically in astrocytes through the astrocyte-specific Aldh111 promoter. Astrocyte-specific expression of eGFP was confirmed by immunohistochemistry using cell typespecific markers for astrocytes, neurons and microglia (Figure 6A). Tagged ribosomes, along with attached astrocyte-specific translating mRNA, were immunoprecipitated (Figure 6B). Sequencing of post-TRAP mRNA (TRAPseq) confirmed enrichment for astrocyte cell type-specific genes and depletion for markers for other cell types (Figure 6C; Supplementary Figure S11), and hence allowed us to determine astrocyte-specific gene expression changes in our experimental models.

7. Anesthesia alters astrocyte gene expression and upregulates reactivity-associated signatures.

To identify how anesthesia altered astrocyte genes, we exposed Aldh111-EGFP-rp113a transgenic mice to 6 h isoflurane and used TRAPseq to isolate astrocyte-specific mRNA. We found that anesthesia altered a wide-programme

of gene expression in astrocytes (Figure 7A; Supplementary Data S2-6). Gene ontology analysis of astrocyte genes altered by anesthesia reveals upregulation of genes in stress-response and pro-apoptotic pathways, and downregulation of genes in pathways related to vasoconstriction and cholesterol efflux (*Apln, Dusp5, Cx3cl1, Arhgap42, Nr1h3, Sirt1, Ptch1, Cav1, Pltp*) (Figure 7B).

Astrocytes are known to alter their transcriptional profiles in response to both acute and chronic disease, a term called reactive astrogliosis. Whilst reactive astrogliosis can be defined in several different ways (Escartin et al., 2021), recent work has determined that the transcriptional response of reactive astrocytes can differ depending on the nature and timing of the insult or disease. We wanted to understand to what extent anesthesia altered transcriptional programs in astrocytes which overlap with deleterious astrocyte changes observed during acute and chronic neurodegenerative disease.

First, we compared how anesthesia altered astrocyte genes associated with acute CNS insults. We used published data to identify astrocyte genes upregulated commonly by two different



UP with Anesthesia in Astrocytes

	GO Terms - Biological Processes	Annotated	Significant	Padj	Odds Ratio
0031953	negative regulation of protein autophosphorylation	9	4	0.00055	15.9
0106072	negative regulation of adenylate cyclase- activating G protein-coupled receptor signaling pathway	9	4	0.02092	15.9
0071276	cellular response to cadmium ion	16	4	0.00612	6.6
0090200	positive regulation of release of cytochrome c from mitochondria	22	5	0.00340	5.8
0045648	positive regulation of erythrocyte differentiation	19	4	0.01161	5.3
0120163	negative regulation of cold-induced thermogenesis	35	7	0.00120	5.0
0051384	response to glucocorticold	46	9	0.00598	4.9
0048147	negative regulation of fibroblast proliferation	32	5	0.01751	3.7
0008625	extrinsic apoptotic signaling pathway via death domain receptors	58	9	0.01630	3.7
:0030593	neutrophil chemotaxis	39	6	0.00339	3.6

GO.ID	GO Terms - Molecular Functions	Annotated	Significant	Padj	Odds Ratio
GO:0070888	E-box binding	27	6	0.0016	5.6
GO:0001968	fibronectin binding	20	4	0.0145	4.9
GO:0005251	delayed rectifier potassium channel activity	21	4	0.0172	4.6
GO:0071889	14-3-3 protein binding	33	5	0.0206	3.5
GO:0001784	phosphotyrosine residue binding	27	4	0.0401	3.4
GO:0030170	pyridoxal phosphate binding	42	6	0.0153	3.3
GO:0015459	potassium channel regulator activity	32	4	0.0681	2.8
GO:0004252	serine-type endopeptidase activity	45	5	0.0663	2.5
GO:0008201	heparin binding	76	8	0.0310	2.3
GO:0016684	oxidoreductase activity, acting on peroxide as	39	4	0.0069	2.2

DOWN with Anesthesia in Astrocytes

0:0045906	negative regulation of vasoccnstriction	8	4	0.00186	20.3
0:0042832	defense response to protozoan	13	5	0.00021	12.7
0:0002052	positive regulation of neuroblast proliferation	23	8	6.1E-06	10.9
0:0090049	regulation of cell migration involved in sprouting angiogenesis	26	9	0.00217	10.9
0:0002320	lymphoid progenitor cell differentiation	13	4	0.00221	9.0
0:0040037	negative regulation of fibroblast growth factor receptor signaling pathway	13	4	0.00249	9.0
0:0070932	histone H3 deacetylation	13	4	0.00249	9.0
0:0010875	positive regulation of cholesterol efflux	17	5	0.00088	8.5
0:0048715	negative regulation of oligodendrocyte differentiation	14	4	0.00335	8.1
0:0045606	positive regulation of epidermal cell differentiation	14	4	0.02007	8.1
O.ID	GO Terms - Molecular Functions	Annotated	Significant	Padj	Odds Ratio
0:0008330	protein tyrosine/threcnine phosphatase activity	9	4	0.00051	16.2
0:0017017	MAP kinase tyrosine/serine/threonine phosphatase activity	10	4	0.00083	13.5
0:0004879	nuclear receptor activity	31	9	8.7E-06	8.4
0.0042056	chemoattractant activity	16	4	0.00571	6.8

0:0042056	chemoattractant activity	16	4	0.00571	6.8
0:0005125	cytokine activity	66	11	0.00019	4.1
0:0043425	bHLH transcription factor binding	24	4	0.05776	4.1
0:0008083	growth factor activity	68	11	0.00031	3.9
0:0005179	hormone activity	37	6	0.07352	3.9
0:0004860	protein kinase inhibitor activity	56	9	0.00549	3.9
0:0051879	Hsp90 protein binding	39	6	0.00937	3.7

Sig Up – *p* value < 0.05

FIGURE 7

(A) Anesthesia alters astrocyte gene expression and upregulates genes associated with both acute and chronic reactive states. Genes significantly induced (red) and suppressed (blue) are highlighted (expression cut-off 1 FPKM, FC > 1.3, p_adj < 0.05) (N = 4 animals per condition). (B) Ontological analysis of astrocyte genes induced and repressed by anesthesia. Top ten most significantly enriched pathways are shown, with pathways with less than 4 significant genes or not relevant to tissue type omitted. (C) Anesthesia overall upregulates pan-reactive astrocyte genes enhanced by both acute LPS and middle cerebral artery occlusion (MCAO). Gene lists derived from Zamanian et al. (2012), re-derived as described in Jiwaji and Hardingham (2022). Fold change astrocyte genes, anesthesia v control (expression cut-off > 1 FPKM, ratio paired 2-tailed t-test). (D) Anesthesia overall upregulates reactive astrocyte genes found to be commonly upregulated in end-stage amyloidopathy (APP/PS1 model) and end-stage tauopathy (MAPT-P301S model). Gene-list from Jiwaji and Hardingham (2022). Fold change astrocyte genes, anesthesia v control (expression cut-off > 1 FPKM, ratio paired 2-tailed t-test).

acute insults (acute LPS-mediated inflammation and ischaemia from middle cerebral artery occlusion (MCAO) from data from Zamanian et al. (2012) as described in Jiwaji et al. (2022). We found that anesthesia significantly upregulated the common set of reactive genes increased by both acute LPS administration and MCAO (Figure 7C). Next, we examined how anesthesia alters genes changed during chronic neurodegenerative disease. We identified genes upregulated by two different proteinopathies associated with Alzheimer's disease (amyloidopathy and tauopathy, as published in Jiwaji et al. (2022)) and found that anesthesia significantly upregulated the common set of astrocyte genes increased by both end-stage amyloidopathy and tauopathy (Figure 7D).



FIGURE 8

Consequences of visual sensory deprivation and light stimulation on astrocyte gene expression, and comparison with astrocyte genes changed by alternative stimulation paradigms and by ageing and disease. (A) TRAPseq identifies astrocyte genes altered by altered visual sensory experience. Genes significantly induced (red) and repressed (blue) are highlighted (expression cut-off > 1 FPKM, FC > 1.3, $p_adj < 0.05$) for normal light conditions v darkness (left) and with 24 h light-exposure (right). (B) Astrocyte genes upregulated by light re exposure overlap with astrocyte genes significantly enhanced by neuronal activity *in vitro* (gene-set from Hasel et al., 2017). Fold change light re-exposure v continuous darkness (expression cut-off > 1 FPKM, ratio paired 2-tailed t-test). (C) (left). Activity-dependent astrocyte genes upregulated by visual sensory stimulation (Normal light conditions v continuous darkness, expression cut-off > 1 FPKM, FC > 2, $p_adj < 0.05$) are significantly enriched in sets of astrocyte genes upregulated after 4 h light exposure in single-cell analysis of visual cortex; drug-induced seizures; and in mice experiencing sleep-deprivation v sleep. (*p-value < 0.05, Fisher's exact test). (C) (right). Activity-dependent astrocyte genes reduced by ageing and in a mouse model of tauopathy. (*p-value < 0.05, Fisher's exact test).

8. Visual sensory-deprivation and light stimulus alter astrocyte gene expression.

By combining the visual sensory deprivation paradigm (described above) with TRAPseq, we identified astrocyte-specific visual cortex gene expression changes to darkness and light re-exposure. We found that visual stimulation altered the expression of hundreds of astrocyte genes (Figure 8A; Supplementary Data S2-7, 2-8), including upregulating astrocyte genes previously described to be altered by increased neuronal activity *in vitro* (Hasel et al., 2017); (Figure 8B). Comparing with other published datasets, we found enrichment of astrocyte genes upregulated by visual sensory experience within gene-sets identified by single-cell sequencing analysis of visual cortex genes to 4 h light exposure (Hrvatin et al., 2018), as well as astrocyte genes upregulated in mice experiencing sleep deprivation (Bellesi et al., 2015) and in mice following seizures induced by PTZ (Sapkota et al., 2022) (Figure 8C, left). This was suggestive of a common set of activity-regulated astrocyte genes altered consistently by different stimulus and experimental paradigms. Astrocyte genes increased by sensory



0.05 for each individual gene, ***p-value < 0.001 for overall downregulation of glycolysis gene-set, 2-way ANOVA).

stimulus were also significantly enriched within astrocyte genesets found to be decreased by ageing (Boisvert et al., 2018) and by neurodegeneration (Jiwaji et al., 2022) (Figure 8C, right), highlighting a potential age/disease related modulation of activity-dependent astrocyte pathways.

9. Anesthesia alters the expression of astrocyte genes regulated by neuronal activity.

We next investigated how anesthesia altered astrocyte genes identified to be regulated by visual sensory deprivation and stimulation. We found that anesthesia overall significantly downregulates astrocyte genes enhanced by light stimulation, and upregulates astrocyte genes suppressed by light stimulation (Figure 9A).

A key function of astrocytes is to uptake glucose and convert this into lactate via glycolysis. According to the astrocyte neuron lactate shuttle (ANLS) hypothesis this acts as a fuel source for nearby neurons. In prior work, we determined that neuronal activity upregulated the expression of astrocyte glycolysis pathway genes, increasing the ability of astrocytes to uptake glucose and produce lactate. We examined the consequences of anesthesia on astrocyte glycolytic gene expression and found that anesthesia overall suppressed astrocyte glycolytic gene expression down-regulating key glycolytic genes including those for glucose uptake (*Slc2a1*), rate-limiting genes for glycolysis (*Pfkp, Pfkl, Pfkm*), and genes regulating lactate production (*Ldha, Ldhb*) (Figure 9B). However, activity-suppression through dark-exposure did not have a significant consequence on astrocyte glycolytic gene expression.

10. Anesthesia alters non-activity dependent astrocyte genes, upregulating astrocyte pathways associated with inflammation and oxidative stress.

Finally, we determined to what extent anesthesia altered astrocyte gene expression independent of activity-mediated effects. Using an



C Astrocyte Genes UP with Anesthesia and Not Activity-Regulated

					Ratio
GO:0090385	phagosome-lysosome fusion	9	3	0.0012	19.3
GO:0071447	cellular response to hydroperoxide	6	3	0.0091	19.2
GO:0006910	phagocytosis, recognition	17	3	0.0478	8.3
GO:0070098	chemokine-mediated signaling pathway	22	3	0.0176	6.1
GO:0048247	lymphocyte chemotaxis	22	3	0.0304	6.1
GO:0042092	type 2 immune response	23	3	0.0253	5.8
GO:0032613	interleukin-10 production	23	3	0.05	5.8
GO:0050829	defense response to Gram-negative bacterium	31	4	0.0075	5.7
GO:0002548	monocyte chemotaxis	24	3	0.0223	5.5
GO:0009880	embryonic pattern specification	44	5	0.0413	5.0
GO.ID	GO Terms - Molecular Functions	Annotated	Significant	Padj	Odds
GO:0008009	chemokine activity	12	3	0.00287	13.1
GO:0015026	coreceptor activity	14	3	0.00457	10.7
GO:0004521	endoribonuclease activity	45	4	0.01663	3.4
GO:0001228	DNA- binding transcription activator activity, RNA poly merase II-specific	270	13	0.01809	2.0
GO:0031490	chromatin DNA binding	78	6	0.02406	3.3
GO:0015293	symporter activity	71	6	0.03129	3.
GO:0005516	calmodulin binding	122	6	0.08499	2.0
GO:0008028	monocarboxylic acid transmembrane transporter activity	26	3	0.09513	5.
GO:0009931	calcium-dependent protein serine/ threonine kinase activity	20	3	0.14003	7.0
			0	0 14976	

		Parino talte d	Cigninean	,	Ratio
GO:0021872	forebrain generation of neurons	36	7	0.04855	9.6
O:0000737	DNA catabolic process, endonucleolytic	21	4	0.00867	9.3
O:0021879	forebrain neuron differentiation	28	5	0.01556	8.6
GO:0045880	positive regulation of smoothened signal	29	5	0.00069	8.2
0:0035522	monoubiquitinated histone H2A deubiquiti	28	4	0.0049	6.6
O:0097300	programmed necrotic cell death	38	5	0.00357	6.0
GO:0030488	tRNA methylation	31	4	0.03178	5.8
0:0060760	positive regulation of response to cytok	33	4	0.04905	5.4
O:0045165	cell fate commitment	143	15	0.00337	4.8
0:0043966	histone H3 acetylation	66	7	0.0021	4.7

iO.ID	GO Terms - Molecular Functions	Annotated	Significant	Padj	Odds Ratio
O:0070888	E-box binding	27	5	0.00047	9.1
GO:0016251	RNA polymerase II general transcription initiation factor activity	31	5	0.0009	7.7
O:0008408	3'-5' exonuclease activity	37	5	0.01166	6.2
O:0004879	nuclear receptor activity	31	4	0.00687	5.9
GO:0008013	beta-catenin binding	63	8	0.00015	5.9
GO:0042054	histone methyltransferase activity	47	5	0.00848	4.7
O:0003697	single-stranded DNA binding	95	9	0.00085	4.2
O:0003684	damaged DNA binding	45	4	0.06687	3.9
GO:0019210	kinase inhibitor activity	60	5	0.09469	3.6
O:1990841	promoter-specific chromatin binding	53	4	0.04196	3.2

FIGURE 10

Consequences of anesthesia on astrocyte genes not regulated by neuronal activity. (A) Astrocyte anesthesia-regulated genes (expression cut-off > 1 FPKM, p_adj < 0.05, FC > 1.3) not regulated by activity identified by removing possible activity-regulated genes as those changed in normal light v dark conditions, 24 h light-re-exposure or with neuronal-activity blockade *in vitro* (expression cut-off > 1 FPKM, unadjusted *p*-value < 0.1). (B) Identified astrocyte non activity-mediated anesthesia-regulated genes are not altered *in vivo* by visual sensory stimulation or *in vitro* by neuronal-activity blockade. Log2 FC expression of astrocyte genes normal light conditions v darkness (top) or in TTX v control (bottom) shown of genes identified in (A). (C) Ontological analysis of astrocyte non-activity-regulated genes induced or repressed by anesthesia. Top ten pathways are shown, with pathways with less than 3 significant genes or fold enrichment < 2 omitted.

identical approach to that described earlier in the paper, we created a combined list of genes altered (expression cut-off > 1 FPKM, unadjusted *p*-value < 0.1) in astrocytes by visual sensory experience (normal light v dark, or with light re-exposure) or *in vitro* by manipulation of neuronal activity using TTX [data from Hasel et al. (2017)], using a higher unadjusted *p*-value to capture any genes that were at all likely to be activity-dependent in all paradigms (Figure 10A; Supplementary Data S2-9). We confirmed that activity-independent astrocyte genes altered by anesthesia did not change both in response to visual sensory-deprivation or following *in vitro* alteration of neuronal activity (Figure 10B). Ontology analysis of activity-independent astrocyte genes altered by anesthesia (Figure 10C) revealed predominantly an upregulation of inflammation-associated pathways, including those regulating cytokine production (*Lefty1*,

Ccl17, Ccl3, Wnt10a, Ccl12, Wnt4), and upregulation of pathways for phagosome-lysosome fusion and immune responses.

Discussion

Anesthesia alters a wide programme of cortical transcription

Although general anesthesia is widely used in humans and animals, the molecular consequences remain poorly understood. Developing a better understanding of the biological pathways altered by anesthesia is especially important because of negative associations in both pre-clinical and clinical contexts. In animals, anesthesia increases brain cell apoptosis (Yon et al., 2005), alters mitochondrial properties (Zhang and Xie, 2012), and worsens neuropathology in models of Alzheimer's disease (Perucho et al., 2010). In clinical studies, anesthesia has been linked to post-operative delirium and long-lasting cognitive impairment (Bratzke et al., 2018).

In this study, we used RNA-sequencing approaches to map the consequences of prolonged volatile anesthesia on cortical transcription. The sensitivity of our methods revealed hundreds of cortical genes that are altered during anesthesia, significantly expanding on the number of genes previously identified with less sensitive methods such as microarray analysis. Genes upregulated by anesthesia are enriched for ontology terms related to inflammation and apoptosis, supporting a detrimental role for prolonged anesthesia on cortical function.

Anesthesia alters astrocyte transcription

The primary target of anesthetic agents has been presumed to be neurons, where they are widely considered to inhibit synaptic firing through GABA receptor activation or NMDA receptor inhibition. However, in our study, we determined that anesthesia has consequences beyond only neurons. We identified transcriptional consequences on total cortical gene expression, as well as focusing on gene expression changes occurring specifically in astrocytes. Astrocytes, the most common non-neuronal cell type in the CNS, are important for several neurosupportive roles including maintaining neurotransmitter, ionic, metabolic and antioxidant homeostasis. Anesthesia has previously been described to act on astrocytes via astrocyte GABA receptors (Chung et al., 2021), and altering astrocyte calcium signalling (Thrane et al., 2012) and gap junction properties (Liu et al., 2016). However, the transcriptional consequences of these effects on astrocyte pathways important for brain function were unknown. In this study, using TRAP-sequencing to isolate astrocytespecific gene expression changes from those in other CNS cell types, we present a detailed description of how anesthesia alters astrocyte transcription, further expanding our understanding of the molecular consequences of anesthesia on non-neuronal CNS cell types.

We found that the transcriptional changes induced by anesthesia in astrocytes overlap with reactive changes seen in response to both acute insults (LPS administration and acute ischaemia through MCA occlusion) and chronic insults (neurodegenerative amyloid and tau pathology). Indeed, the fact that 6 h anesthesia induced reactive changes in astrocytes previously identified in response to chronic dementia-associated pathology highlights the potential deleterious consequences of anesthesia, especially in those with pre-existing neurodegenerative disease.

CNS and astrocyte activity-responsive genes identified by visual sensory deprivation and light stimulation

It is widely believed that the primary mechanism of anesthesia function is through global suppression of neuronal activity through GABA activation or NMDA-receptor inhibition. Altered neuronal activity has been described by ourselves and others to alter transcriptional networks in both neurons and astrocytes to modulate pathways important for neuronal and brain homeostasis and health. Therefore, the consequence of general anesthesia on these activitydependent transcriptional pathways was of particular interest to us.

In this study, using visual sensory deprivation and light stimulation paradigms, we have revealed how altered neuronal activity regulates CNS transcription in non-anesthetized animals. We have identified hundreds of genes (across all cell-types and specifically in astrocytes) that are regulated by visual sensory stimulation. The sensitivity and added transcriptional depth possible through the TRAP-seq approaches used adds to the smaller number of astrocyte and neuronal genes previously identified to be altered by light stimulation using single-cell approaches (Hrvatin et al., 2018). Furthermore, we found that visually responsive astrocyte genes overlap with astrocyte genes altered in other studies that involved dysregulated neuronal activity such as seizures (Sapkota et al., 2022) and sleep-deprivation (Bellesi et al., 2017), consistent with a common set of activity-responsive astrocyte genes. We also found that astrocyte genes upregulated by activity are enriched in sets of astrocyte genes found to be reduced by ageing (Boisvert et al., 2018) and neurodegeneration (Jiwaji et al., 2022). As activity-dependent astrocyte pathways are essential for metabolic homeostasis, it would be interesting to understand the extent to which reductions in these pathways contribute towards brain metabolic dysfunction observed in both ageing and degenerating brains.

Anesthesia dysregulates activity-dependent genes, suppressing activity-regulated homeostatic pathways and enhancing activity-suppressed pro-death pathways

In keeping with the proposed mechanism of action as an activator of GABA and inhibitor of NMDA receptors, we determined that anesthesia is a strong suppressor of activity-regulated CNS and astrocyte genes. This includes suppression of activity-regulated neuroprotective and pro-synaptogenesis genes (Bdnf, Arc, Npas4, Homer1). Indeed, the negative consequences of anesthesia on suppressing activity-dependent genes extends beyond the level of activity-suppression possible by visual-sensory deprivation and is only revealed by examining genes found to be regulated in conditions of total neuronal activity blockade using TTX in vitro. Comparing genes that are changed by total activity blockade revealed that anesthesia upregulates activity-suppressed pro-death genes and suppresses activity-enhanced genes in astrocytes responsible for CNS metabolic homeostasis. The fact that these detrimental effects are not seen in visual-sensory deprivation is of course not unsurprising, given that eye-closure or sleeping is not associated with the harmful effects attributed to anesthesia.

Overall, these findings reveal how anesthesia suppresses activitydependent pathways in the cortex, leading to reduced expression of genes associated with brain homeostasis and boosting genes associated with cell-death. These changes may contribute to observed deleterious consequences of anesthesia, especially as dysregulation of brain metabolism has been demonstrated to occur in patients with delirium using nuclear imaging (Haggstrom et al., 2017). Our follow-on work now seeks to understand the consequences of targeting restoration of activitydependent pathways during anesthesia to reduce deleterious transcriptional changes for therapeutic benefit.

Activity-independent consequences of anesthesia drive deleterious and inflammation-associated responses

Beyond consequences on activity-dependent gene expression, we also identified that anesthesia altered expression of hundreds of CNS and astrocyte genes that were not modulated by neuronal firing as identified by visual sensory deprivation or *in vitro* blockade of neuronal activity. These findings are consistent with anesthesia having wider consequences on CNS beyond simply one of acting as a pharmacological inhibitor of neuronal activity.

We identified activity-independent consequences of anesthesia on pathways related to apoptosis and inflammation responses, including upregulating pathways related to mitochondrialassociated apoptosis pathways and lipoxygenase production. In astrocytes, we found that anesthesia alters the expression of nonactivity regulated genes related to inflammation including those regulating phagosome-lysosome function, chemokine signalling and cytokine production. These findings are consistent with anesthesia driving further deleterious and inflammationassociated responses in neuronal and non-neuronal cells beyond those detrimental effects seen by neuronal activity suppression alone.

The extent of inflammation-associated changes driven by anesthesia that are independent of activity-regulated effects points towards a broader pro-inflammatory role of anesthesia on CNS cells. Indeed, anesthesia has been postulated to have immune modulating effects, and the mechanisms that drive these deleterious pro-inflammatory effects (including upstream transcription factors and regulators) now requires to be studied. Furthermore, microglia-astrocyte interactions have been shown to be important in regulating astrocyte responses to inflammation (Liddelow et al., 2017). Therefore, it is likely that non-activity mediated changes of anesthesia on astrocytes may be downstream of uncharacterised microglia responses. A fuller understanding of the interactions between astrocytes and microglia (as well between astrocytes and other non-cellular elements within the brain milieu) during anesthesia may reveal important pathways that could be targeted to reduce the potentially deleterious inflammatory consequences of anesthesia identified in this work.

Limitations of work

An important limitation is that the data presented in this work represents changes at the level of gene expression, which may not translate to protein-level or functional consequences. The use of the translating ribosome affinity purification methodology mitigates this somewhat, as this will only sequence mRNA molecules that are being actively translated. Hence, these are more likely to represent gene expression changes reflecting changes to protein synthesis. Furthermore, we have previously determined that alterations in activity-controlled apoptosis genes by suppression of neuronal activity did lead to changes in protein concentrations (Léveillé et al., 2010). However, our work will not identify changes to cellular functions by anesthesia through controls downstream of protein synthesis (for example, changes in protein degradation pathways). Our work has investigated the consequences of a single anesthesia agent (isoflurane) on CNS and astrocyte pathways. The extent to which consequences of using other anesthesia agents overlap with our findings remains to be determined. Finally, our work does not address the long-term consequences of anesthesia on brain and astrocyte geneexpression. Ongoing work now aims to investigate how geneexpression perturbations persist following recovery from anesthesia, and the extent to which these may drive long-lasting impairments in cognition.

Concluding remarks

Our study provides a comprehensive insight into the transcriptional consequences of anesthesia on global CNS and astrocyte transcription. By identifying how anesthesia alters genes that are both activity-dependent and activity-independent, we have identified stress and inflammation-associated responses associated with loss of metabolic homeostasis and enhancement of pro-death pathways. This rich dataset will provide a valuable resource for researchers using anesthesia in brain research as well as those exploring mechanisms behind the clinically-associated cognitive complications of anesthesia.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-13054.

Ethics statement

The animal study was reviewed and approved by the Bioresearch and Veterinary Services, University of Edinburgh. All procedures described were performed either in compliance with the UK Animals (Scientific Procedures) Act 1986 and carried out under project license numbers 70/9008 and P1351480E.

Author contributions

ZJ, NM and JM carried out experiments and interpreted data. KE, XH, and OD performed bioinformatic analysis. ZJ, SC and GEH co-designed the study. SC and GEH co-supervised the project. ZJ and GEH co-wrote the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was funded by the Wellcome Trust and the UK Dementia Research Institute, which receives its funding from DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Anderson, C. M., and Swanson, R. A. (2000). Astrocyte glutamate transport: Review of properties, regulation, and physiological functions. *Glia* 32, 1–14. doi:10.1002/1098-1136(200010)32:1<1::aid-glia10>3.0.co;2-w

Baxter, P. S., Bell, K. F. S., Hasel, P., Kaindl, A. M., Fricker, M., Thomson, D., et al. (2015). Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. *Nat. Commun.* 6, 6761. doi:10.1038/ncomms7761

Baxter, P. S., Márkus, N. M., Dando, O., He, X., Al-Mubarak, B. R., Qiu, J., et al. (2021). Targeted de-repression of neuronal Nrf2 inhibits α -synuclein accumulation. Cell. Death Dis. 12, 218. doi:10.1038/s41419-021-03507-z

Bélanger, M., Allaman, I., and Magistretti, P. J. (2011). Brain energy metabolism: Focus on astrocyte-neuron metabolic cooperation. *Cell. Metab.* 14, 724–738. doi:10. 1016/j.cmet.2011.08.016

Bell, K. F. S., and Hardingham, G. E. (2011). The influence of synaptic activity on neuronal health. *Curr. Opin. Neurobiol.* 21, 299–305. doi:10.1016/j.conb.2011.01.002

Bellesi, M., de Vivo, L., Chini, M., Gilli, F., Tononi, G., and Cirelli, C. (2017). Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex. *J. Neurosci.* 37, 5263–5273. doi:10.1523/JNEUROSCI.3981-16.2017

Bellesi, M., de Vivo, L., Tononi, G., and Cirelli, C. (2015). Effects of sleep and wake on astrocytes: Clues from molecular and ultrastructural studies. *BMC Biol.* 13, 66. doi:10. 1186/s12915-015-0176-7

Boisvert, M. M., Erikson, G. A., Shokhirev, M. N., and Allen, N. J. (2018). The aging astrocyte transcriptome from multiple regions of the mouse brain. *Cell. Rep.* 22, 269–285. doi:10.1016/j.celrep.2017.12.039

Bratzke, L. C., Koscik, R. L., Schenning, K. J., Clark, L. R., Sager, M. A., Johnson, S. C., et al. (2018). Cognitive decline in the middle-aged after surgery and anaesthesia: Results from the Wisconsin registry for alzheimer's prevention cohort. *Anaesthesia* 73, 549–555. doi:10.1111/anae.14216

Chung, W., Wang, D. S., Khodaei, S., Pinguelo, A., and Orser, B. A. (2021). GABA(A) receptors in astrocytes are targets for commonly used intravenous and inhalational general anesthetic drugs. *Front. Aging Neurosci.* 13, 802582. doi:10.3389/fnagi.2021. 802582

Culley, D. J., Baxter, M. G., Yukhananov, R., and Crosby, G. (2004). Long-term impairment of acquisition of a spatial memory task following isoflurane-nitrous oxide anesthesia in rats. *Anesthesiology* 100, 309–314. doi:10.1097/0000542-200402000-00020

Deighton, R. F., Márkus, N. M., Al-Mubarak, B., Bell, K. F. S., Papadia, S., Meakin, P. J., et al. (2014). Nrf2 target genes can be controlled by neuronal activity in the absence of Nrf2 and astrocytes. *Proc. Natl. Acad. Sci. U. S. A.* 111, E1818–E1820. doi:10.1073/pnas.1402097111

Doyle, J. P., Dougherty, J. D., Heiman, M., Schmidt, E. F., Stevens, T. R., Ma, G., et al. (2008). Application of a translational profiling approach for the comparative analysis of CNS cell types. *Cell* 135 (4), 749–762. doi:10.1016/j.cell.2008.10.029

Dutton, R. C., Maurer, A. J., Sonner, J. M., Fanselow, M. S., Laster, M. J., and Eger, E. I. (2002). Isoflurane causes anterograde but not retrograde amnesia for pavlovian fear conditioning. *Anesthesiology* 96, 1223–1229. doi:10.1097/0000542-200205000-00027

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnetp.2023.1216366/ full#supplementary-material

SUPPLEMENTARY FIGURE S3

Consequences of anesthesia on genes suppressed by visual sensory stimulation. Genes suppressed by normal light conditions (A) or light re-exposure (B) compared to darkness (expression cut-off > 1 FPKM, padj < 0.05, FC > 2, ratio paired 2-tailed *t*-test) are not overall down-regulated or upregulated by anesthesia.

SUPPLEMENTARY FIGURE S11

qtPCR confirmation of selected genes determined to be altered by RNAseq analysis throughout manuscript.(A) qtPCR validation of anesthesia-mediated suppression of *Arc* and *Bdnf*. (Mean \pm SEM fold change RNA expression v 6 h anesthesia normalised to house-keeping gene *Rpl13a*, N = 5 animals per condition, **p* value < 0.05, two-tailed *t*-test). (B) qtPCR validation of visual sensory deprivation-mediated suppression of *Arc* and *Bdnf*. (Mean \pm SEM fold change RNA expression v 7 days darkness normalised to house-keeping gene *Rpl13a*, N = 4 animals per condition, **p* value < 0.05, 1-way ANOVA with multiple comparisons). (C) qtPCR validation of TRAP-mediated enrichment or depletion of cell type-specific markers (Mean \pm SEM fold change RNA expression v input sample normalised to house-keeping gene *Rpl13a*, N = 3 animals per condition, **p* value < 0.05, 1-way ANOVA for enriched or depleted gene-sets).

Escartin, C., Galea, E., Lakatos, A., O'Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., et al. (2021). Reactive astrocyte nomenclature, definitions, and future directions. *Nat. Neurosci.* 24, 312–325. doi:10.1038/s41593-020-00783-4

Hadjihambi, A., Karagiannis, A., Theparambil, S. M., Ackland, G. L., and Gourine, A. V. (2020). The effect of general anaesthetics on brain lactate release. *Eur. J. Pharmacol.* 881, 173188. doi:10.1016/j.ejphar.2020.173188

Haggstrom, L. R., Nelson, J. A., Wegner, E. A., and Caplan, G. A. (2017). 2-18Ffluoro-2-deoxyglucose positron emission tomography in delirium. *J. Cereb. Blood Flow. Metab.* 37, 3556–3567. doi:10.1177/0271678X17701764

Hasel, P., Dando, O., Jiwaji, Z., Baxter, P., Todd, A. C., Heron, S., et al. (2017). Neurons and neuronal activity control gene expression in astrocytes to regulate their development and metabolism. *Nat. Commun.* 8, 15132. doi:10.1038/ncomms15132

Heiman, M., Kulicke, R., Fenster, R. J., Greengard, P., and Heintz, N. (2014). Cell type-specific mRNA purification by translating ribosome affinity purification (TRAP). *Nat. Protoc.* 9, 1282–1291. doi:10.1038/nprot.2014.085

Hertz, L., and Chen, Y. (2016). Importance of astrocytes for potassium ion (K+) homeostasis in brain and glial effects of K+ and its transporters on learning. *Neurosci. Biobehav. Rev.* 71, 484–505. doi:10.1016/j.neubiorev.2016.09.018

Hrvatin, S., Hochbaum, D. R., Nagy, M. A., Cicconet, M., Robertson, K., Cheadle, L., et al. (2018). Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex. *Nat. Neurosci.* 21, 120–129. doi:10.1038/s41593-017-0029-5

Ioannou, M. S., Jackson, J., Sheu, S. H., Chang, C. L., Weigel, A. V., Liu, H., et al. (2019). Neuron-astrocyte metabolic coupling protects against activity-induced fatty acid toxicity. *Cell*. 177, 1522–1535.e14. doi:10.1016/j.cell.2019.04.001

Jiwaji, Z., and Hardingham, G. E. (2022). Good, bad, and neglectful: Astrocyte changes in neurodegenerative disease. *Free Radic. Biol. Med.* 182, 93–99. doi:10.1016/j. freeradbiomed.2022.02.020

Jiwaji, Z., Tiwari, S. S., Avilés-Reyes, R. X., Hooley, M., Hampton, D., Torvell, M., et al. (2022). Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. *Nat. Commun.* 13, 135. doi:10.1038/s41467-021-27702-w

Keller, G. B., Bonhoeffer, T., and Hubener, M. (2012). Sensorimotor mismatch signals in primary visual cortex of the behaving mouse. *Neuron* 74, 809–815. doi:10.1016/j. neuron.2012.03.040

Kim, S., Kim, H., and Um, J. W. (2018). Synapse development organized by neuronal activity-regulated immediate-early genes. *Exp. Mol. Med.* 50, 1–7. doi:10.1038/s12276-018-0025-1

Lacar, B., Linker, S. B., Jaeger, B. N., Krishnaswami, S. R., Barron, J. J., Kelder, M. J. E., et al. (2016). Nuclear RNA-seq of single neurons reveals molecular signatures of activation. *Nat. Commun.* 7, 11022. doi:10.1038/ncomms11022

Léveillé, F., Papadia, S., Fricker, M., Bell, K. F. S., Soriano, F. X., Martel, M. A., et al. (2010). Suppression of the intrinsic apoptosis pathway by synaptic activity. *J. Neurosci.* 30, 2623–2635. doi:10.1523/JNEUROSCI.5115-09.2010

Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* 541, 481–487. doi:10.1038/nature21029

Lin, Y., Bloodgood, B. L., Hauser, J. L., Lapan, A. D., Koon, A. C., Kim, T. K., et al. (2008). Activity-dependent regulation of inhibitory synapse development by Npas4. *Nature* 455, 1198–1204. doi:10.1038/nature07319

Liu, X., Gangoso, E., Yi, C., Jeanson, T., Kandelman, S., Mantz, J., et al. (2016). General anesthetics have differential inhibitory effects on gap junction channels and hemichannels in astrocytes and neurons. *Glia* 64, 524–536. doi:10.1002/glia. 22946

Lukatch, H. S., Kiddoo, C. E., and MacIver, M. B. (2005). Anesthetic-induced burst suppression EEG activity requires glutamate-mediated excitatory synaptic transmission. *Cereb. Cortex* 15, 1322–1331. doi:10.1093/cercor/bhi015

Pan, Z., Lu, X. F., Shao, C., Zhang, C., Yang, J., Ma, T., et al. (2011). The effects of sevoflurane anesthesia on rat hippocampus: A genomic expression analysis. *Brain Res.* 1381, 124–133. doi:10.1016/j.brainres.2011.01.020

Papadia, S., Soriano, F. X., Léveillé, F., Martel, M. A., Dakin, K. A., Hansen, H. H., et al. (2008). Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. *Nat. Neurosci.* 11, 476–487. doi:10.1038/nn2071

Pavel, M. A., Petersen, E. N., Wang, H., Lerner, R. A., and Hansen, S. B. (2020). Studies on the mechanism of general anesthesia. *Proc. Natl. Acad. Sci. U. S. A.* 117, 13757–13766. doi:10.1073/pnas.2004259117

Perucho, J., Rubio, I., Casarejos, M. J., Gomez, A., Rodriguez-Navarro, J. A., Solano, R. M., et al. (2010). Anesthesia with isoflurane increases amyloid pathology in mice models of Alzheimer's disease. *J. Alzheimers. Dis.* 19, 1245–1257. doi:10. 3233/JAD-2010-1318

Pollina, E. A., Gilliam, D. T., Landau, A. T., Lin, C., Pajarillo, N., Davis, C. P., et al. (2023). A NPAS4-NuA4 complex couples synaptic activity to DNA repair. *Nature* 614, 732–741. doi:10.1038/s41586-023-05711-7

Qiu, J., Dando, O., Febery, J. A., Fowler, J. H., Chandran, S., and Hardingham, G. E. (2020). Neuronal activity and its role in controlling antioxidant genes. *Int. J. Mol. Sci.* 21, 1933. doi:10.3390/ijms21061933

Ries, C. R., and Puil, E. (1993). Isoflurane prevents transitions to tonic and burst firing modes in thalamic neurons. *Neurosci. Lett.* 159, 91–94. doi:10.1016/0304-3940(93) 90806-v

Robinson, T. N., and Eiseman, B. (2008). Postoperative delirium in the elderly: Diagnosis and management. *Clin. Interv. Aging* 3, 351-355. doi:10.2147/cia.s2759

Saab, A. S., Tzvetavona, I. D., Trevisiol, A., Baltan, S., Dibaj, P., Kusch, K., et al. (2016). Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism. *Neuron* 91, 119–132. doi:10.1016/j.neuron.2016.05.016

Sapkota, D., Kater, M. S. J., Sakers, K., Nygaard, K. R., Liu, Y., Koester, S. K., et al. (2022). Activity-dependent translation dynamically alters the proteome of the perisynaptic astrocyte process. *Cell. Rep.* 41, 111474. doi:10.1016/j.celrep.2022.111474

Slupe, A. M., and Kirsch, J. R. (2018). Effects of anesthesia on cerebral blood flow, metabolism, and neuroprotection. *J. Cereb. Blood Flow. Metab.* 38, 2192–2208. doi:10. 1177/0271678X18789273

Son, Y. (2010). Molecular mechanisms of general anesthesia. Korean J. Anesthesiol. 59, 3–8. doi:10.4097/kjae.2010.59.1.3

Thrane, A. S., Rangroo Thrane, V., Zeppenfeld, D., Lou, N., Xu, Q., Nagelhus, E. A., et al. (2012). General anesthesia selectively disrupts astrocyte calcium signaling in the awake mouse cortex. *Proc. Natl. Acad. Sci. U. S. A.* 109, 18974–18979. doi:10.1073/pnas. 1209448109

Upton, D. H., Popovic, K., Fulton, R., and Kassiou, M. (2020). Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brain. *Sci. Rep.* 10, 9366. doi:10.1038/s41598-020-66122-6

Weber, B., and Barros, L. F. (2015). The astrocyte: Powerhouse and recycling center. Cold Spring Harb. Perspect. Biol. 7, 0203966-a20416. doi:10.1101/cshperspect.a020396

Weiser, T. G., Regenbogen, S. E., Thompson, K. D., Haynes, A. B., Lipsitz, S. R., Berry, W. R., et al. (2008). An estimation of the global volume of surgery: A modelling strategy based on available data. *Lancet* 372, 139–144. doi:10.1016/ S0140-6736(08)60878-8

Xie, Z., Culley, D. J., Dong, Y., Zhang, G., Zhang, B., Moir, R. D., et al. (2008). The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level *in vivo. Ann. Neurol.* 64, 618–627. doi:10.1002/ana.21548

Yon, J. H., Daniel-Johnson, J., Carter, L. B., and Jevtovic-Todorovic, V. (2005). Anesthesia induces neuronal cell death in the developing rat brain via the intrinsic and extrinsic apoptotic pathways. *Neuroscience* 135, 815–827. doi:10.1016/j.neuroscience. 2005.03.064

Zamanian, J. L., Xu, L., Foo, L. C., Nouri, N., Zhou, L., Giffard, R. G., et al. (2012). Genomic analysis of reactive astrogliosis. *J. Neurosci.* 32, 6391–6410. doi:10.1523/ JNEUROSCI.6221-11.2012

Zhang, Y., and Xie, Z. (2012). Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. *Ann. Neurol.* 71, 630–698. doi:10.1002/ana.23683